Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes

Luca D'Onofrio; Lucia Coraggio; Annalisa Zurru; Angela Carlone; Carmen Mignogna; Chiara Moretti; Ernesto Maddaloni; Raffaella Buzzetti

doi:10.1016/j.diabres.2021.109022

Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes

Diabetes Res Clin Pract. 2021 Sep:179:109022. doi: 10.1016/j.diabres.2021.109022. Epub 2021 Aug 24.

Authors

Luca D'Onofrio¹, Lucia Coraggio², Annalisa Zurru², Angela Carlone², Carmen Mignogna², Chiara Moretti², Ernesto Maddaloni², Raffaella Buzzetti²

Affiliations

¹ Experimental Medicine Department, Sapienza University of Rome, Italy. Electronic address: luca.donofrio@uniroma1.it.
² Experimental Medicine Department, Sapienza University of Rome, Italy.

Abstract

In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.

Keywords: CGM; Diabetes; Glucose control; Sars-Cov-2; Vaccination.

MeSH terms

Blood Glucose
Blood Glucose Self-Monitoring
COVID-19*
Diabetes Mellitus, Type 1* / drug therapy
Glucose
Humans
RNA, Viral
SARS-CoV-2
Vaccination

Substances

Blood Glucose
RNA, Viral
Glucose